Title: 68Ga-DOTATATE PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse: Intraindividual comparison with 11C-Choline
Abstract: 347 Objectives To compare the clinical value and uptake of 68Ga-DOTATATE and 11C-Choline in prostate cancer patients after initial treatment and during follow-up who presented increased PSA levels in spite of being on hormone treatment (HT), and thus classified as having HT resistance. Methods We studied 20 HT-resistant patients who presented biochemical recurrence, with a median trigger PSA level of 4.5 ng/mL (range: 0.70-97 ng/mL). Within 1-2 weeks, a PET/CT study was performed with 68Ga-DOTATATE and 11C-Choline with an approximately dose of 100 MBq and 400 MBq, respectively, using a 64-slice PET/CT with time-of-flight correction. The maximum SUV (SUVm) was measured in all abnormal foci. Correlative imaging, histopathology and/or clinical follow-up were considered as reference standard. Results 68Ga-DOTATATE PET/CT demonstrated positive findings in 13/20 patients (65%) whereas 11C-Choline was positive in 10/20 patients (50%). PET findings were discordant in 6 patients and 68Ga-DOTATATE detected more lesions in 5 of them. The following lesions were identified at the prostate bed (6/6), lymph nodes (26/24) and bone (17/14), for 68Ga-DOTATATE and 11C-Choline, respectively. 11C-Choline SUVm where higher than those from 68Ga-DOTATATE (6.5±3.2 vs. 4.7±2.0, n=45, p=0.0021). However, a significant correlation was found among both tracers’ SUVm (r=0.41, n=45, p=0.0049). Conclusions In our patient population 68Ga-DOTATATE PET/CT detected recurrent lesions in a larger proportion of HT resistant prostate cancer patients than 11C-Choline. More studies are needed in order to test for the possible complementary value of these techniques and for the 68Ga-DOTATATE potential of in vivo assessment of neuroendocrine differentiation of advanced prostate cancer lesions.
Publication Year: 2013
Publication Date: 2013-05-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot